↓ Skip to main content

Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed…

Overview of attention for article published in Frontiers in oncology, November 2023
Altmetric Badge

Mentioned by

twitter
2 X users

Citations

dimensions_citation
1 Dimensions

Readers on

mendeley
8 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma
Published in
Frontiers in oncology, November 2023
DOI 10.3389/fonc.2023.1197340
Pubmed ID
Authors

Laura Rosiñol, Benjamin Hebraud, Albert Oriol, Anne-Laurène Colin, Rafael Ríos Tamayo, Cyrille Hulin, María Jesús Blanchard, Denis Caillot, Anna Sureda, Miguel Teodoro Hernández, Bertrand Arnulf, Maria-Victoria Mateos, Margaret Macro, Jesús San-Miguel, Karim Belhadj, Juan José Lahuerta, M. Brigid Garelik, Joan Bladé, Philippe Moreau

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 8 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 8 100%

Demographic breakdown

Readers by professional status Count As %
Librarian 1 13%
Student > Ph. D. Student 1 13%
Student > Bachelor 1 13%
Researcher 1 13%
Unknown 4 50%
Readers by discipline Count As %
Medicine and Dentistry 3 38%
Chemistry 1 13%
Unknown 4 50%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 November 2023.
All research outputs
#20,673,680
of 25,394,764 outputs
Outputs from Frontiers in oncology
#11,324
of 22,440 outputs
Outputs of similar age
#251,079
of 356,960 outputs
Outputs of similar age from Frontiers in oncology
#334
of 897 outputs
Altmetric has tracked 25,394,764 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 22,440 research outputs from this source. They receive a mean Attention Score of 3.0. This one is in the 29th percentile – i.e., 29% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 356,960 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 17th percentile – i.e., 17% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 897 others from the same source and published within six weeks on either side of this one. This one is in the 11th percentile – i.e., 11% of its contemporaries scored the same or lower than it.